Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (Abstract)

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.In this double-blind trial, we randomly assigned 3730 patients with class II, III (...) , or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure.During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization

2020 NEJM

2. Heart Failure With Reduced Ejection Fraction: A Review. (Abstract)

ventricular dilatation and adverse cardiac remodeling. Assessment for heart failure begins with obtaining a medical history and physical examination. Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thresholds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measured by echocardiography. Treatment strategies include the use of diuretics to relieve symptoms and application of an expanding armamentarium of disease-modifying (...) , sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF. Device therapies may be beneficial in specific subpopulations, such as cardiac resynchronization therapy in patients with interventricular dyssynchrony, transcatheter mitral valve repair

2020 JAMA

3. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction (Full text)

Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Jul 7;76(1):1-13. doi: 10.1016/j.jacc.2020.05.015. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction , , , , , , Affiliations Expand Affiliations 1 Medical University of South

2020 EvidenceUpdates PubMed abstract

4. CCS Heart Failure Guidelines Update: Focus on FMR, SGLT2 Inhibitors, ARNI in HFpEF, and Amyloidosis (Full text)

on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis or transthyretin cardiac amyloidosis; (3 (...) CCS Heart Failure Guidelines Update: Focus on FMR, SGLT2 Inhibitors, ARNI in HFpEF, and Amyloidosis CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis - Canadian Journal of Cardiology Go search , P159-169, February 01, 2020 Powered By Mendeley CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis

2020 Canadian Cardiovascular Society PubMed abstract

5. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease

commentary was sought but none was received. Committee comments Committee comments 3.5 The committee noted that the procedure may be contraindicated in patients who have an electronic implant (such as a cardiac pacemaker or defibrillator). Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights (...) Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Interventional procedures guidance Published: 5 August 2020 www.nice.org.uk/guidance/ipg677 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

6. Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials

Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Int J Nurs Stud Actions . 2020 Jun 16;110:103689. doi: 10.1016/j.ijnurstu.2020.103689. Online ahead of print. Effects of self-management interventions on heart failure

2020 EvidenceUpdates

7. Beta-blockers for congestive heart failure in children. (Abstract)

Beta-blockers for congestive heart failure in children. Beta-blockers are an essential part of standard therapy in adult congestive heart failure and therefore, are expected to be beneficial in children. However, congestive heart failure in children differs from that in adults in terms of characteristics, aetiology, and drug clearance. Therefore, paediatric needs must be specifically investigated. This is an update of a Cochrane review previously published in 2009.To assess the effect of beta (...) the included trials.We identified four new studies for the review update; the review now includes seven studies with 420 participants. Four small studies with 20 to 30 children each, and two larger studies of 80 children each, showed an improvement of congestive heart failure with beta-blocker therapy. A larger study with 161 participants showed no evidence of benefit over placebo in a composite measure of heart failure outcomes. The included studies showed no significant difference in mortality or heart

2020 Cochrane

8. mHealth education interventions in heart failure. (Abstract)

mHealth education interventions in heart failure. Heart failure (HF) is a chronic disease with significant impact on quality of life and presents many challenges to those diagnosed with the condition, due to a seemingly complex daily regimen of self-care which includes medications, monitoring of weight and symptoms, identification of signs of deterioration and follow-up and interaction with multiple healthcare services. Education is vital for understanding the importance of this regimen (...) , and adhering to it. Traditionally, education has been provided to people with heart failure in a face-to-face manner, either in a community or a hospital setting, using paper-based materials or video/DVD presentations. In an age of rapidly-evolving technology and uptake of smartphones and tablet devices, mHealth-based technology (defined by the World Health Organization as mobile and wireless technologies to achieve health objectives) is an innovative way to provide health education which has the benefit

2020 Cochrane

9. Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction (Full text)

Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 15;127:73-83. doi: 10.1016/j.amjcard.2020.04.011. Epub 2020 Apr 24. Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction , , , , Affiliations Expand Affiliations 1 Medical Device Consultants, Ridgewood, New Jersey. Electronic address: meddevconsultant@aol.com. 2 Division

2020 EvidenceUpdates PubMed abstract

10. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials

Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Thromb Res Actions . 2020 Jun;190:122-128. doi: 10.1016/j.thromres.2020.04.017. Epub 2020 Apr 18. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials , , , , , , , Affiliations Expand Affiliations 1 Department of Pharmacy, Renji Hospital, School of Medicine

2020 EvidenceUpdates

11. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure

Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Heart Actions . 2020 Jun 22;heartjnl-2019-316429. doi: 10.1136/heartjnl-2019-316429. Online ahead of print. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Cardiovascular Imaging Unit, San Raffaele Scientific Institute, Milan, Italy claudia.marini@outlook.com. 2 Heart Failure Clinic, Clinical Cardiology, San Raffaele Scientific Institute, Milan

2020 EvidenceUpdates

12. Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association

Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Share on Jump to Free Access article Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , DNP, ANP, FAHA, Vice Chair , PhD, RN , PhD, RN , MD, MS , PhD, RN, FAHA , MSHI, RN-BC , PhD, RPh, FAHA , PhD , PhD Lisa Kitko , Colleen K. McIlvennan , Julie T. Bidwell , J. Nicholas Dionne-Odom , Shannon M. Dunlay , Lisa M. Lewis , Ginny Meadows , Elisabeth L.P. Sattler , Richard Schulz , Anna

2020 American Heart Association

13. Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association

Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies (...) . By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , PhD, RN, Vice Chair , MD, MSPH , PhD, NP, FAHA , MD, MPH , PhD, RN, FAHA , PhD, MSN, FAHA , PhD, RN, FAHA , ANP, CNS, FAHA , PhD, MBA, RN Connie White-Williams , Laura P. Rossi , Vera A. Bittner , Andrea Driscoll

2020 American Heart Association

14. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 May 26;141(21):1693-1703. doi: 10.1161/CIRCULATIONAHA.119.045066. Epub 2020 Apr 17. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

2020 EvidenceUpdates

15. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. (Abstract)

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhibitors) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional (...) HFrEF.In this cross-trial analysis, we estimated treatment effects of comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACE inhibitor or ARB and β blocker) in patients with chronic HFrEF by making indirect comparisons of three pivotal trials, EMPHASIS-HF (n=2737), PARADIGM-HF (n=8399), and DAPA-HF (n=4744). Our primary endpoint was a composite of cardiovascular death or first hospital admission for heart failure; we also

2020 Lancet

16. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (Abstract)

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction (...) of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group (hazard ratio, 0.93; 95% CI, 0.81 to 1.06). The composite of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1032

2020 NEJM

17. Position Statement on COVID-19 and Acute Heart Failure: screening the critically ill

of heart failure, whilst nearly 60% had elevated biochemical markers consistent with acute cardiac injury [4]. In two separate cohort studies from Wuhan [3,5], the proportion of COVID-19 patients with evidence of cardiac injury [as defined by elevated levels of high sensitivity troponin (hsTn) with or without other biochemical markers] ranged from 20 to 28%. In both studies, patients with elevated hsTn were older and more likely to have a range of cardiovascular comorbidities including hypertension (...) , diabetes, coronary artery disease and prior heart failure. In both studies, an elevated hsTn was associated with a marked increase in mortality: 50-60% in those with an elevated hsTn compared with a mortality rate of 5-10% for those who had a normal hsTn during hospitalisation. In addition, COVID-19 patients with elevated hsTn during admission experienced higher rates of acute respiratory distress syndrome (ARDS) necessitating higher rates of non-invasive and invasive ventilation, acute renal failure

2020 Cardiac Society of Australia and New Zealand

18. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

2020 EvidenceUpdates

19. Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure

L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med 2020;March 11:[Epub ahead of print]. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 2020;March 23:[Epub ahead of print]. Share via: Clinical Topics: Keywords: Acute Coronary Syndrome, Anticoagulants, Arrhythmias, Cardiac, Cardiac Surgical Procedures, Metabolic Syndrome X, Angina, Stable, Heart (...) Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure Feature | Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure - American College of Cardiology ') Search All Types Search or Menu This article was authored by Joel D. Schilling, MD, PhD , Washington University School of Medicine, St. Louis, MO; Ashwin K. Ravichandran, MD, FACC , St. Vincent's Medical Group, Indianapolis, IN; and Stacy A. Mandras, MD, FACC , Oschner

2020 American College of Cardiology

20. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. (Abstract)

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. In our 2015 systematic review and meta-analysis of cardiovascular outcome trials for glucose-lowering drugs or strategies in people with or at risk of type 2 diabetes, we reported a modest reduction in atherosclerotic cardiovascular events and an increased risk (...) of heart failure, but with heterogeneous effects by drug or intervention type. In view of the completion of many large cardiovascular outcome trials since our previous analysis, including trials of novel drugs that have shown beneficial effects on cardiovascular outcomes, we aimed to update our analysis to incorporate these findings.We did an updated systematic review and meta-analysis of large cardiovascular outcome trials of glucose-lowering drugs or strategies in people with or at risk of type 2

2020 The lancet. Diabetes & endocrinology